ArticleFrontiers in pharmacology2017
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mapping the landscape of managed entry agreements: a systematic review of global frameworks, system-level components, and implementation challenges.Frontiers in pharmacology · 2026Pooled it
- Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.Applied health economics and health policy · 2022Pooled it
- A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Socioeconomic Determinants of Access to Medicines Among Romanian Patients with Chronic Diseases: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Stakeholders' experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands.Acta oncologica (Stockholm, Sweden) · 2026Article
- Managed Entry Agreements for Pharmaceutical Products in Three Maghreb Countries: Payer and Supplier Perspectives.Journal of market access & health policy · 2025Article
- Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.Clinical drug investigation · 2025Article
- A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025Article
- An analysis of compassionate access programmes for novel oncology drugs.Irish journal of medical science · 2025Article
- Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis.Breast cancer (Dove Medical Press) · 2025Article
- The evolving value assessment of cancer therapies: Results from a modified Delphi study.Health policy OPEN · 2024Article
- Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.PharmacoEconomics - open · 2024Article
- Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs.Pharmacy (Basel, Switzerland) · 2024Article
- Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access?Healthcare (Basel, Switzerland) · 2024Article
- Uptake and availability of new outpatient cancer medicines in 2010-2021 in Nordic countries - survey of competent authorities.BMC health services research · 2023Article
- Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.JAMA health forum · 2023Article
- A National Cancer Grid pooled procurement initiative, India.Bulletin of the World Health Organization · 2023Article
- Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective.Healthcare (Basel, Switzerland) · 2023Article
- Reporting reimbursement price decisions for onco-hematology drugs in Spain.Frontiers in public health · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.